BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Clinical trial NCT06756932 · RECRUITING

Trial details

NCT number: NCT06756932
Sponsor: BeOne Medicines
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Hormone-receptor-positive Breast Cancer HER2-negative Breast Cancer Metastatic Breast Cancer

Start date: 2025-02-04
Primary completion: 2027-07-30
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.